DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn, SS | - |
dc.contributor.author | Jeon, BY | - |
dc.contributor.author | Park, SJ | - |
dc.contributor.author | Choi, DH | - |
dc.contributor.author | Ku, SH | - |
dc.contributor.author | Cho, SN | - |
dc.contributor.author | Sung, YC | - |
dc.date.accessioned | 2016-04-01T08:11:12Z | - |
dc.date.available | 2016-04-01T08:11:12Z | - |
dc.date.created | 2013-07-04 | - |
dc.date.issued | 2013-06-12 | - |
dc.identifier.issn | 0264-410X | - |
dc.identifier.other | 2013-OAK-0000027753 | - |
dc.identifier.uri | https://oasis.postech.ac.kr/handle/2014.oak/27418 | - |
dc.description.abstract | Improvement to the immunogenicity of DNA vaccines was evaluated in a Mycobacterium tuberculosis (MTB) infection mouse model examining the combined effects of nonlytic Fc-fused IL-7 DNA (IL-7-nFc) and Flt3-ligand fused Mtb32 (F-Mtb32) DNA. Mice were treated with conventional chemotherapy for 6 weeks from 4 weeks after aerosol infection of MTB. Following the start of chemotherapy, DNA immunizations were administered five times with 2-week intervals. Coadministration of IL-7-nFc and F-Mtb32 DNA given during chemotherapy synergistically enhanced the magnitude of Mtb32-specific T cell responses and sustained for one-year after the last immunization assessed by IFN-gamma ELISPOT assay. After dexamethasone treatment, a significantly reduced MTB reactivation was observed in mice received both IL-7-nFc and F-Mtb32 DNA, compared with F-MTb32 DNA alone or with control mice. In addition, mice treated with IL-7-nFc and F-Mtb32 DNA together showed improved lung pathology and reduced pulmonary inflammation values relative to F-Mtb32 DNA or saline injected mice. Intracellular cytokine staining revealed that the protection levels induced by combination therapy with IL-7-nFc and F-Mtb32 DNA was associated with enhanced Mtb32-specific IFN-gamma secreting CD4(+) T cell responses and CD8(+) T cell responses stimulated with CTL epitope peptide in the lungs and spleens. These data suggest that IL-7-nFc as a novel TB adjuvant may facilitate therapeutic TB DNA vaccine to the clinics through significant enhancement of codelivered DNA vaccine-induced T cell immunity. (C) 2013 Elsevier Ltd. All rights reserved. | - |
dc.description.statementofresponsibility | X | - |
dc.language | English | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.relation.isPartOf | VACCINE | - |
dc.title | Nonlytic Fc-fused IL-7 synergizes with Mtb32 DNA vaccine to enhance antigen-specific T cell responses in a therapeutic model of tuberculosis | - |
dc.type | Article | - |
dc.contributor.college | 융합생명공학부 | - |
dc.identifier.doi | 10.1016/J.VACCINE.2013.04.029 | - |
dc.author.google | Ahn S.-S., Jeon B.-Y., Park S.-J., Choi D.-H., Ku S.-H., Cho S.-N., Sung Y.-C. | - |
dc.relation.volume | 31 | - |
dc.relation.issue | 27 | - |
dc.relation.startpage | 2884 | - |
dc.relation.lastpage | 2890 | - |
dc.contributor.id | 10053752 | - |
dc.relation.journal | VACCINE | - |
dc.relation.sci | SCI | - |
dc.collections.name | Journal Papers | - |
dc.type.rims | ART | - |
dc.identifier.bibliographicCitation | VACCINE, v.31, no.27, pp.2884 - 2890 | - |
dc.identifier.wosid | 000320970600007 | - |
dc.date.tcdate | 2019-02-01 | - |
dc.citation.endPage | 2890 | - |
dc.citation.number | 27 | - |
dc.citation.startPage | 2884 | - |
dc.citation.title | VACCINE | - |
dc.citation.volume | 31 | - |
dc.contributor.affiliatedAuthor | Sung, YC | - |
dc.identifier.scopusid | 2-s2.0-84878470214 | - |
dc.description.journalClass | 1 | - |
dc.description.journalClass | 1 | - |
dc.description.wostc | 6 | - |
dc.description.scptc | 6 | * |
dc.date.scptcdate | 2018-05-121 | * |
dc.type.docType | Article | - |
dc.subject.keywordPlus | MYCOBACTERIUM-TUBERCULOSIS | - |
dc.subject.keywordPlus | IMMUNE-RESPONSES | - |
dc.subject.keywordPlus | ADJUVANT IL-7 | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | MICE | - |
dc.subject.keywordPlus | POLYPROTEIN | - |
dc.subject.keywordPlus | HOMEOSTASIS | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | MTB72F | - |
dc.subject.keywordAuthor | Tuberculosis | - |
dc.subject.keywordAuthor | IL-7-nFc | - |
dc.subject.keywordAuthor | Mtb32 | - |
dc.subject.keywordAuthor | DNA vaccine | - |
dc.subject.keywordAuthor | Adjuvant | - |
dc.subject.keywordAuthor | Immunotherapy | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
library@postech.ac.kr Tel: 054-279-2548
Copyrights © by 2017 Pohang University of Science ad Technology All right reserved.